Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1-Reference-Cited by-同舟云学术

Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1

Published:2015-05-21 Issue:21 Volume:125 Page:3360-3363
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Loghavi Sanam¹^ORCID,Pemmaraju Naveen¹,Kanagal-Shamanna Rashmi¹^ORCID,Mehrotra Meenakshi¹^ORCID,Medeiros L. Jeffrey¹^ORCID,Luthra Raja¹,Lin Pei¹,Huh Yang¹^ORCID,Kantarjian Hagop M.²,Cortes Jorge E.²,Verstovsek Srdan²,Patel Keyur P.¹

Affiliation:

1. Department of Hematopathology, MD Anderson Cancer Center, The University of Texas, Houston, TX

2. Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/21/3360/1386502/3360.pdf

Reference8 articles.

1. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.;Tefferi;Leukemia,2014

2. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.;Rumi;Blood,2014

3. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value.;Vannucchi;Leukemia,2014

4. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.;Nangalia;N Engl J Med,2013

5. Somatic mutations of calreticulin in myeloproliferative neoplasms.;Klampfl;N Engl J Med,2013

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease;Frontiers in Cell and Developmental Biology;2024-03-26

2. BCR::ABL1‐positive chronic myeloid leukaemia with CALR mutation;Clinical and Experimental Pharmacology and Physiology;2023-02-15

3. Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib;Clinical Case Reports;2023-01

4. Frequency of coexistence and kinetics of the BCR-ABL1 transcript level and allele burden of JAK2V617F and CALR Type 1, 2 gene mutations in patients with chronic myeloid leukemia;Russian journal of hematology and transfusiology;2020-09-21

5. Philadelphia+ Chronic Myeloid Leukemia with CALR Mutation: A Case Report and Literature Review;Cancer Research and Treatment;2020-07-15